At the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Peter Staley asks Dr. Joe Eron about the good news on a challenging drug – newly-approved Selzentry – and the very potent new protease inhibitor, Prezista.
NEW! Scroll down to comment on this story.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
If you don't understand one of the words in this article,
just double-click it. A window will open with a definition
from CancerWEB's On-line Medical Dictionary. If the double-click feature
doesn't work in your browser, you can enter the word below:
